Emanuel E Petricoin

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Clinical applications of proteomics: proteomic pattern diagnostics
    Emanuel E Petricoin
    FDA NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Mammary Gland Biol Neoplasia 7:433-40. 2002
  2. ncbi Clinical proteomics: application at the bedside
    Emanuel F Petricoin
    FDA-NCI Clinical Proteomics Program, Center for Biologic Evaluation and Research, Food and Drug Administration, NIH, Bethesda, MD, USA
    Contrib Nephrol 141:93-103. 2004
  3. ncbi Proteomic approaches in cancer risk and response assessment
    Emanuel F Petricoin
    FDA NCI, Clinical Proteomics Program, Building 29A, Room 2D12, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Trends Mol Med 10:59-64. 2004
  4. ncbi SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Curr Opin Biotechnol 15:24-30. 2004
  5. ncbi Clinical proteomics: revolutionizing disease detection and patient tailoring therapy
    Emanuel Petricoin
    NCI FDA Clinical Proteomics Program, Office of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Proteome Res 3:209-17. 2004
  6. ncbi Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Toxicol Pathol 32:122-30. 2004
  7. ncbi Proteomic analysis at the bedside: early detection of cancer
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Trends Biotechnol 20:S30-4. 2002
  8. ncbi Clinical applications of proteomics
    Emanuel F Petricoin
    U S Food and Drug Administration National Cancer Institute Clinical Proteomics Program, Center for Biologic Evaluation and Research, U S Food and Drug Administration, Rockville, MD 20852, USA
    J Nutr 133:2476S-2484S. 2003
  9. ncbi Clinical proteomics: Applications for prostate cancer biomarker discovery and detection
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Urol Oncol 22:322-8. 2004
  10. ncbi Medical applications of microarray technologies: a regulatory science perspective
    Emanuel F Petricoin
    Division of Therapeutic Products, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland 20892, USA
    Nat Genet 32:474-9. 2002

Detail Information

Publications79

  1. ncbi Clinical applications of proteomics: proteomic pattern diagnostics
    Emanuel E Petricoin
    FDA NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Mammary Gland Biol Neoplasia 7:433-40. 2002
    ..The new concept that is introduced by this platform is that the underlying identities of the proteins that comprise the patterns are not known and do not need to be known; the pattern itself becomes the diagnostic...
  2. ncbi Clinical proteomics: application at the bedside
    Emanuel F Petricoin
    FDA-NCI Clinical Proteomics Program, Center for Biologic Evaluation and Research, Food and Drug Administration, NIH, Bethesda, MD, USA
    Contrib Nephrol 141:93-103. 2004
  3. ncbi Proteomic approaches in cancer risk and response assessment
    Emanuel F Petricoin
    FDA NCI, Clinical Proteomics Program, Building 29A, Room 2D12, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Trends Mol Med 10:59-64. 2004
    ..These technologies are being developed for early detection and risk assessment, therapeutic targeting and patient-tailored therapy...
  4. ncbi SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Curr Opin Biotechnol 15:24-30. 2004
    ..The biomarkers found by SELDI-TOF-based pattern recognition analysis are mostly low molecular weight fragments produced at the specific tumor microenvironment...
  5. ncbi Clinical proteomics: revolutionizing disease detection and patient tailoring therapy
    Emanuel Petricoin
    NCI FDA Clinical Proteomics Program, Office of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Proteome Res 3:209-17. 2004
    ..The analysis of human cancer can be used as a model for how clinical proteomics is having an impact at the bedside for early detection, rational therapeutic targeting, and patient-tailored therapy...
  6. ncbi Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Toxicol Pathol 32:122-30. 2004
    ..These fragments may one day be harvested by circulating nanoparticles designed to absorb, enrich and amplify the diagnostic biomarker repertoire generated even at the critical initial stages of toxicity...
  7. ncbi Proteomic analysis at the bedside: early detection of cancer
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Trends Biotechnol 20:S30-4. 2002
    ..Today, new proteomic technologies are being used to discover new diagnostic and prognostic biomarkers for the early detection and treatment of cancer that will have important implications at the bedside...
  8. ncbi Clinical applications of proteomics
    Emanuel F Petricoin
    U S Food and Drug Administration National Cancer Institute Clinical Proteomics Program, Center for Biologic Evaluation and Research, U S Food and Drug Administration, Rockville, MD 20852, USA
    J Nutr 133:2476S-2484S. 2003
    ....
  9. ncbi Clinical proteomics: Applications for prostate cancer biomarker discovery and detection
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Urol Oncol 22:322-8. 2004
    ..These diagnostic fragments may one day be harvested by circulating nanoparticles, designed to absorb, enrich, and amplify the repertoire of diagnostic biomarkers generated-even at the critical, initial stages of carcinogenesis...
  10. ncbi Medical applications of microarray technologies: a regulatory science perspective
    Emanuel F Petricoin
    Division of Therapeutic Products, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland 20892, USA
    Nat Genet 32:474-9. 2002
    ....
  11. ncbi Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, CBER, FDA, Bethesda, MD 20892, USA
    Proteomics 4:2357-60. 2004
    ..We reflect on the important lessons gleaned from the Wright brothers' attempts at controlled heavier-than-air flight as a model for perseverance and a view to the very near future for proteomic pattern diagnostics...
  12. ncbi Serum proteomic patterns for detection of prostate cancer
    Emanuel F Petricoin
    Food and Drug Administration FDA National Cancer Institute NCI Clinical Proteomics Program, Department of Therapeutic Proteins Center for Biologics Evaluation and Research CBER, Bethesda, MD, USA
    J Natl Cancer Inst 94:1576-8. 2002
    ..If validated in future series, serum proteomic pattern diagnostics may be of value in deciding whether to perform a biopsy on a man with an elevated PSA level...
  13. ncbi Clinical proteomics: translating benchside promise into bedside reality
    Emanuel F Petricoin
    FDA NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Nat Rev Drug Discov 1:683-95. 2002
    ..Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient...
  14. ncbi Use of proteomic patterns in serum to identify ovarian cancer
    Emanuel F Petricoin
    Food and Drug Administration National Institutes of Health Clinical Proteomics Program, Department of Therapeutic Proteins Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Lancet 359:572-7. 2002
    ..We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary...
  15. ncbi Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy
    Katherine R Calvo
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biosci Rep 25:107-25. 2005
    ....
  16. ncbi Opportunities for nanotechnology-based innovation in tissue proteomics
    David H Geho
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Biomed Microdevices 6:231-9. 2004
    ....
  17. ncbi Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy
    Kristen M Carr
    Laboratory of Pathology, National Cancer Institute National Institutes of Health, 10 Center Drive, MSC 1500, Bethesda, MD 20892 1500, USA
    Hum Genomics 1:134-40. 2004
    ....
  18. ncbi Clinical proteomics and biomarker discovery
    Donald J Johann
    NCI FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1022:295-305. 2004
    ..Clinically engineered mass spectroscopy systems are essential for the further development and validation of multiplexed biomarkers that have shown tremendous promise for the early detection of disease...
  19. ncbi Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy
    Emanuel F Petricoin
    US Food and Drug Administration National Cancer Institute Clinical Proteomics Program, Office of Cellular and Gene Therapy, Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    J Clin Oncol 23:3614-21. 2005
    ..We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material...
  20. ncbi Pathology of the future: molecular profiling for targeted therapy
    Virginia Espina
    National Cancer Institute, Laboratory of Pathology, Bethesda, Maryland, USA
    Cancer Invest 23:36-46. 2005
    ....
  21. ncbi Clinical proteomics for cancer biomarker discovery and therapeutic targeting
    Rene C Krieg
    FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Technol Cancer Res Treat 1:263-72. 2002
    ....
  22. ncbi STUDENTJAMA. Molecular technologies for personalized cancer management
    Rani K Hasan
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    JAMA 291:1644-5. 2004
  23. ncbi Proteomic applications for the early detection of cancer
    Julia D Wulfkuhle
    NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 3:267-75. 2003
    ..Studies that profile proteomic patterns in body fluids also present new opportunities for the development of novel, highly sensitive diagnostic tools for the early detection of cancer...
  24. ncbi Molecular diagnostics: an FDA perspective
    Ali M Ardekani
    Department of Therapeutic Proteins, CBER, FDA, Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 3:129-40. 2003
    ....
  25. ncbi Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research
    J Carl Barrett
    National Cancer Institute Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Adv Hematol Oncol 1:302-6. 2003
    ..Its infrastructure supports the iterative flow of information from the bench to the bedside and from the bedside to the bench, expediting the delivery of molecularly based therapeutics to cancer patients...
  26. ncbi Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma
    Katherine M Sheehan
    United States Food and Drug Administration (FDA)-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA
    Mol Cell Proteomics 4:346-55. 2005
    ..Extending these findings to the bedside will require the development of optimized protocols and reference standards. We have developed a reference standard based on a mixture of phosphorylated peptides to begin to address this challenge...
  27. ncbi Proteomic analysis of human prostate cancer
    Mamoun Ahram
    Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Carcinog 33:9-15. 2002
    ..The marked heterogeneity of the observed protein alterations may have significance with regard to tumor biology and research strategies for molecular profiling analyses of human prostate cancer...
  28. ncbi Biomarkers of ovarian tumours
    Amy V Rapkiewicz
    Laboratory of Pathology, National Cancer Institute National Institutes of Health, Bethesda, MD 20892 1500, USA
    Eur J Cancer 40:2604-12. 2004
    ..Here, we review the studies that are involved in biomarker development for the detection of ovarian cancer...
  29. ncbi Reverse phase protein microarrays for theranostics and patient-tailored therapy
    Virginia Espina
    Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA
    Methods Mol Biol 441:113-28. 2008
    ..The results of which pathways are "in use" can then be correlated with biological and clinical information and serve as both a diagnostic and a therapeutic guide: thus providing a "theranostic" endpoint...
  30. ncbi Clinical potential of proteomics in the diagnosis of ovarian cancer
    Ali M Ardekani
    Proteomics Program, NCI-FDA Clinical Proteomics Program, Center for Biologics Evaluation and Research, Food and Drug Administration and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute and Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 2:312-20. 2002
    ..Serum proteomic pattern analysis might be applied ultimately in medical screening clinics, as a supplement to the diagnostic work-up and evaluation...
  31. ncbi Proteomic approaches to the diagnosis, treatment, and monitoring of cancer
    Julia D Wulfkuhle
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Adv Exp Med Biol 532:59-68. 2003
    ....
  32. ncbi Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications
    Mamoun Ahram
    Pathogenetics Unit, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Proteomics 3:413-21. 2003
    ..In light of these results, we conclude that ethanol-fixed tissues can be successfully utilized for proteomic analyses...
  33. ncbi Using decision forest to classify prostate cancer samples on the basis of SELDI-TOF MS data: assessing chance correlation and prediction confidence
    Weida Tong
    Center for Toxicoinformatics, Division of Biometry and Risk Assessment, National Center for Toxicological Research FDA, 3900 NCTR Road, HFT020, Jefferson, AK 72079, USA
    Environ Health Perspect 112:1622-7. 2004
    ..DF should be equally applicable to other omics data such as gene expression data or metabolomic data. The DF algorithm is available upon request...
  34. ncbi Dilution of protein gel stain results in retention of staining capacity
    Rene C Krieg
    Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biotechniques 35:376-8. 2003
  35. ncbi Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays
    Julia D Wulfkuhle
    Center for Cancer Research, National Cancer Institute NIH, Building 29A Room 2B20, 8000 Rockville Pike, Bethesda, MD 20892, USA
    Proteomics 3:2085-90. 2003
    ....
  36. ncbi Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer
    Paul C Herrmann
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, NIH, Bethesda, MD, USA
    Proteomics 3:1801-10. 2003
    ..This analysis points to a role for nuclear DNA encoded mitochondrial proteins in carcinogenesis; underscoring their potential as targets for therapy while highlighting the need for full characterization of the mitochondrial proteome...
  37. ncbi Protein microarrays: meeting analytical challenges for clinical applications
    Lance A Liotta
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Cell 3:317-25. 2003
    ....
  38. ncbi Signal pathway profiling of prostate cancer using reverse phase protein arrays
    Robert L Grubb
    Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Proteomics 3:2142-6. 2003
    ..With the advent of molecular targeted therapeutics, the identification, characterization and monitoring of the signaling events within actual human biopsies will be critical for patient-tailored therapy...
  39. ncbi Proteomic analysis of lymph
    Lee V Leak
    Clinical Proteomics Program of Therapeutic Proteins, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proteomics 4:753-65. 2004
    ..By bringing the technologies of proteomics to bear on the analysis of lymph, it is possible to detect proteins in lymph that are quantitatively and qualitatively differentially expressed from those of plasma...
  40. ncbi Proteomic technologies to study diseases of the lymphatic vascular system
    Lee V Leak
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 979:211-28; discussion 229-34. 2002
    ....
  41. ncbi Blasting into the microworld of tissue proteomics: a new window on cancer
    David H Geho
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Rm 2A33, 10 Center Drive, Building 10, Bethesda, MD 20892, USA
    Clin Cancer Res 10:825-7. 2004
  42. ncbi Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures
    Robert L Grubb
    Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    J Proteome Res 8:3044-54. 2009
    ....
  43. ncbi Importance of communication between producers and consumers of publicly available experimental data
    Lance A Liotta
    FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, CCR, Bethesda, MD 20892, USA
    J Natl Cancer Inst 97:310-4. 2005
    ..Such disputes, however, should not divert us from the validation of this promising new approach...
  44. ncbi Analysis of albumin-associated peptides and proteins from ovarian cancer patients
    Mark S Lowenthal
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Clin Chem 51:1933-45. 2005
    ....
  45. ncbi The promise of proteomics
    Lance A Liotta
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD, USA
    Clin Adv Hematol Oncol 1:460-2. 2003
  46. ncbi Reverse-phase protein microarrays for tissue-based analysis
    Runa Speer
    National Institutes of Health, National Cancer Institute, Center for Cancer Research, FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Bethesda, MD 20892, USA
    Curr Opin Mol Ther 7:240-5. 2005
    ....
  47. ncbi Protein microarray detection strategies: focus on direct detection technologies
    Virginia Espina
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Room B1B53, Bldg 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunol Methods 290:121-33. 2004
    ..Herein, we discuss detection strategies and challenges for protein microarray technology, focusing on direct detection of protein microarrays...
  48. ncbi Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients
    Bih Rong Wei
    Molecular Pathology Unit, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    PLoS ONE 4:e7670. 2009
    ..Improved means for early detection and reliable patient monitoring are needed to increase survival...
  49. ncbi Serum proteomics in cancer diagnosis and management
    Kevin P Rosenblatt
    Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland 20892, USA
    Annu Rev Med 55:97-112. 2004
    ..With this approach, rapid and cost-effective tests with exquisite clinical sensitivity and specificity are emerging. These tools may dramatically change how disease is detected, monitored, and managed...
  50. ncbi Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP)
    David M Berman
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 4:812-8. 2004
    ..GRASP represents an advance in the field of proteomics as it detects protein interactions present in cells as they exist in their native tissue microenvironment...
  51. ncbi Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays
    Lu Charboneau
    Laser Capture Microdissection Core Facility, and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Brief Funct Genomic Proteomic 1:305-15. 2002
    ....
  52. ncbi Proteomics of human breast ductal carcinoma in situ
    Julia D Wulfkuhle
    Women's Cancers Section, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 62:6740-9. 2002
    ..Proteomic analysis of DCIS revealed differential expression patterns distinct from previous nucleic acid-based studies and identified new facets of the earliest stage of breast cancer progression...
  53. ncbi Protein microarrays: molecular profiling technologies for clinical specimens
    Virginia Espina
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute NIH, Building 10 Room B1B53, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Proteomics 3:2091-100. 2003
    ..A subclass of protein microarrays, Reverse Phase Arrays, created to meet these challenges, has been optimized for use with tissue specimens, and is now in use for the analysis of biopsy samples for clinical trial research...
  54. ncbi Use of proteomic analysis to monitor responses to biological therapies
    Virginia Espina
    National Cancer Institute, NIH, Building 10, Room B1B53, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 4:83-93. 2004
    ..Ultimately, proteomics and genomics will become integrated into cancer patient management through the design and tracking of individualised therapy...
  55. ncbi CSF proteome: a protein repository for potential biomarker identification
    Martin J Romeo
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Expert Rev Proteomics 2:57-70. 2005
    ..This review highlights some of the promising areas of cerebrospinal fluid proteomic research and their clinical applications...
  56. ncbi Biomarker amplification by serum carrier protein binding
    Arpita I Mehta
    Howard Hughes Medical Institute, Bethesda, MD 20814, USA
    Dis Markers 19:1-10. 2003
    ..These findings shift the focus of biomarker detection to the carrier protein and its biomarker content...
  57. ncbi The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology
    Amy Rapkiewicz
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer 111:173-84. 2007
    ..Reverse-phase protein microarray (RPPM) technology has been applied successfully to the quantitative analysis of breast, ovarian, prostate, and colorectal cancers using frozen surgical specimens...
  58. ncbi Novel approaches to visualization and data mining reveals diagnostic information in the low amplitude region of serum mass spectra from ovarian cancer patients
    Donald J Johann
    NCI FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Dis Markers 19:197-207. 2003
    ..This region can then be selected and studied to identify the exact location and amplitude of the diagnostic biomarkers...
  59. ncbi Use of proteomic patterns to screen for gastrointestinal malignancies
    Andrew L Feldman
    Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 135:243-7. 2004
  60. ncbi An investigation into the human serum "interactome"
    Ming Zhou
    Laboratory of Proteomics and Analytical Technologies, SAIC Frederick, Inc, National Cancer Institute, Frederick, MD, USA
    Electrophoresis 25:1289-98. 2004
    ..Among the 210 proteins identified, 73% and 67% were not found in previous studies of the low-molecular-weight or whole-serum proteome, respectively...
  61. ncbi The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer
    Monica Brown Jones
    Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892 1500, USA
    Clin Cancer Res 9:44-51. 2003
    ..We hypothesized that new growth factors may be identified through the molecular analysis of ovarian tumors as they exist in their native environment...
  62. ncbi Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
    Emanuel F Petricoin
    Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Cellular and Gene Therapy, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:3431-40. 2007
    ..These results suggest that phosphoprotein mapping of the Akt/mTOR pathway should be studied further as a means to select patients to receive mTOR/IRS pathway inhibitors before administration of chemotherapy...
  63. ncbi Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy
    Runa Speer
    University of Tubingen, Faculty of Medicine, Department of Obstetrics and Gynecology, Calwer Str 7, 72076 Tubingen, Germany, and Department of Surgery, Inova Fairfax Hospital Cancer Center, Falls Church, VA, USA
    Cancer Genomics Proteomics 4:157-64. 2007
    ..This "wiring diagram" can serve as the basis for both, selection of a therapy and patient stratification...
  64. ncbi Reverse-phase protein microarrays: application to biomarker discovery and translational medicine
    Amy VanMeter
    George Mason University, Center for Applied Proteomics and Molecular Medicine, Manassas, VA 20110, USA
    Expert Rev Mol Diagn 7:625-33. 2007
    ..This class of microarray can be used to interrogate cellular samples, serum or body fluids. This review focuses on the application of reverse-phase protein microarrays for translational research and therapeutic drug target discovery...
  65. ncbi Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform
    Lance A Liotta
    Clin Chem 54:3-5. 2008
  66. ncbi Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
    Julia D Wulfkuhle
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
    J Proteome Res 7:1508-17. 2008
    ..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis...
  67. ncbi Human Proteinpedia enables sharing of human protein data
    Suresh Mathivanan
    Nat Biotechnol 26:164-7. 2008
  68. ncbi Molecular network analysis using reverse phase protein microarrays for patient tailored therapy
    Runa Speer
    , Faculty of Medicine, Department of Obstetrics and Gynecology, , Germany
    Adv Exp Med Biol 610:177-86. 2008
  69. ncbi 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers
    Ge Zhou
    Department of Biochemistry University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, USA
    Mol Cell Proteomics 1:117-24. 2002
    ....
  70. ncbi Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml
    David K Ornstein
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Urol 172:1302-5. 2004
    ....
  71. ncbi A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples
    Mary F Lopez
    PerkinElmer Life and Analytical Sciences, Wellesley, MA 02481 4008, USA
    Clin Chem 53:1067-74. 2007
    ..To use mass spectrometry (MS) of serum proteins for early detection, a seamless workflow is needed that provides an opportunity for rapid profiling along with direct identification of the underpinning ions...
  72. ncbi Laser-capture microdissection
    Virginia Espina
    Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Blvd. MS 4E3, Manassas, Virginia, USA
    Nat Protoc 1:586-603. 2006
    ..Herein we provide a thorough description of LCM techniques, with an emphasis on tips and troubleshooting advice derived from LCM users. The total time required to carry out this protocol is typically 1-1.5 h...
  73. ncbi The blood peptidome: a higher dimension of information content for cancer biomarker discovery
    Emanuel F Petricoin
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas Virginia 20110, USA
    Nat Rev Cancer 6:961-7. 2006
    ..Measuring panels of peptidome markers might be more sensitive and specific than conventional biomarker approaches. We discuss the advantages and disadvantages of various methods for studying the peptidome...
  74. ncbi Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays
    Julia D Wulfkuhle
    Center for Applied Proteomics Molecular Medicine, George Mason University, Manassas, VA, USA
    Nat Clin Pract Oncol 3:256-68. 2006
    ....
  75. ncbi Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold
    Lance A Liotta
    Center for Applied Proteomics and Molecular Medicine, College of Arts and Sciences, George Mason University, Manassas, Virginia 20110, USA
    J Clin Invest 116:26-30. 2006
    ..Villanueva et al. now suggest that this suppression may in fact be preventing biomarker generation...
  76. ncbi General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer
    Lance A Liotta
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, USA
    Gynecol Oncol 88:S25-8; discussion S37-42. 2003
  77. ncbi Analysis of mass spectral serum profiles for biomarker selection
    Habtom W Ressom
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Bioinformatics 21:4039-45. 2005
    ..We present low-level methods for the processing of mass spectral data and a machine learning method that combines support vector machines, with particle swarm optimization for biomarker selection...
  78. ncbi Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health
    Michael T Lotze
    Translational Research, University of Pittsburgh Molecular Medicine Institute, Pittsburgh, Pennsylvania, USA
    J Immunother (1997) 28:79-119. 2005
    ..Concrete recommendations for current application and enabling further development in cancer biometrics are summarized. This will allow a more informed, rapid, and accurate assessment of novel cancer therapies...
  79. ncbi Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer
    Claudio Belluco
    Department of Surgery, CRO IRCCS, National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano PN, Italy
    Ann Surg Oncol 14:2470-6. 2007
    ..Mass spectrometry (MS)-based profiling was used to determine whether ion fingerprints could distinguish women with stage 1 breast cancer from women without breast cancer...